New Pharmaceutical Industry Developments for 2021

AUSTIN, Texas - March 4, 2021 - PRLog -- The start of this new decade will forever be identified with the coronavirus pandemic, and it has shoved the normally low profile pharmaceutical industry out of the background into the spotlight.

The past year was marked by rapid vaccine development. 2021 will be different, as much of the Pharma industry focuses its energies on mass vaccine production.

Within this pandemic environment, we take a deeper look at the key trends to watch across all of the pharmaceutical industry in 2021.

The Success Of MRNA Coronavirus Vaccines Opens The Door To A Wider Genomic Medicine Revolution

When we first wrote about coronavirus vaccine development a year ago, we shared the skepticism of many health experts who, based on previous experience, believed it would take at least 18 months to develop and deploy a successful vaccine – at the very quickest!

Little did we know at the time that scientists at Moderna had developed a theoretical messenger RNA-based vaccine design in just 48 hours before the US had its first recorded case – and they had a working prototype ready to test on lab animals just 6 weeks after that.

The crash vaccine development programs at Moderna (and fellow mRNA vaccine pioneer Pfizer BioNTech) have accelerated the adoption of mRNA vaccine technology by many years – and the potential for treating other diseases using this technology is great – making this one of our top bellwether trends for 2021.

Speaking to MIT Technology Review, Moderna's CEO Stéphane Bancel, whose company's stock has made him a millionaire on paper, points out that the mRNA components can be reprogrammed – just like software. "The way we make mRNA for one vaccine is exactly the same as for another," he says. "Because mRNA is an information molecule, the difference between our Covid vaccine, Zika vaccine, and the flu vaccine is only the order of the nucleotides."

In theory, this new technology could allow scientists to develop vaccines and clinical treatments for many of the most stubborn diseases, including sickle-cell anemia, HIV, herpes, infant respiratory virus, liver disease, and malaria.

Coronavirus Vaccines Will Become A Recurring Revenue Stream

The coronavirus vaccine has not been well-controlled in many nations, and unfortunately, Covid-19 has taken advantage of this opportunity to develop new viral strains, which complicate efforts to successfully vaccinate populations in time to achieve herd immunity.

Read more...https://formaspace.com/articles/pharmaceuticals/new-pharm...